Enliven Therapeutics spiked to a 52-week high after the precision oncology firm unveiled positive proof of concept data from an early-stage trial of its.
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) were down 3.9% during trading on Monday after an insider sold shares in the company. The company traded as low as $18.64 and last traded at $18.64. Approximately 9,380 shares traded hands during trading, a decline of 94% from the average daily volume of 144,773 […]
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3 9% After Insider Selling themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $18.30, but opened at $18.96. Enliven Therapeutics shares last traded at $18.77, with a volume of 11,556 shares changing hands. Wall Street Analyst Weigh In Separately, Mizuho started coverage on Enliven Therapeutics in […]